The positive allosteric modulator morantel binds at noncanonical subunit interfaces of neuronal nicotinic acetylcholine receptors

Journal of Neuroscience

Volumn 29, Issue 27, 2009, Pages 8734-8742

  Seo, Seungmae ^a   Henry, Jonathan T ^a   Lewis, Amanda H ^a   Wang, Nan ^a   Levandoski, Mark M ^a  

^a GRINNELL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CYSTEINE; MORANTEL; MUTANT PROTEIN; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA3BETA2; NICOTINIC RECEPTOR; PROTEIN SUBUNIT; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHANNEL GATING; CONTROLLED STUDY; EVOKED RESPONSE; FEMALE; MOLECULAR MODEL; NERVE CELL; NERVE CELL MEMBRANE POTENTIAL; NONHUMAN; PARTIAL AGONISM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; VOLTAGE CLAMP;

ALLOSTERIC REGULATION; ANIMALS; EVOKED POTENTIALS; FEMALE; MORANTEL; NEURONS; PROTEIN BINDING; PROTEIN SUBUNITS; RATS; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 67650473173     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1859-09.2009     Document Type: Article

References (44)

1. Akk G, Steinbach JH (2005) Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site. J Neurosci 25:1992-2001.
2. Arias HR (2000) Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. Neurochem Int 36:595-645.
3. Arias HR, Bhumireddy P, Spitzmaul G, Trudell JR, Bouzat C (2006) Molecular mechanisms and binding site location for the noncompetitive antagonist crystal violet on nicotinic acetylcholine receptors. Biochemistry 45:2014-2026.
4. Bertrand D, Gopalakrishnan M (2007) Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 74:1155-1163.
5. Bertrand D, Cooper E, Valera S, Rungger D, Ballivet M (1991) Electrophysiology of neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes following nuclear injection of genes of cDNAs. Methods Neurosci 4:174-193.
6. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1:CD005593.
7. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK (2001) Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411:269-276.
8. Buhr A, Sigel E (1997) Apoint mutation in the γ2 subunit if γ-aminobutyric acid type A receptors results in altered benzodiazepine binding site specificity. Proc Natl Acad Sci U S A 94:8824-8829.
9. Celie PH, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB, Sixma TK (2004) Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 41:907-914.
10. Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC (1997) Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4, and hα7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 280:346-356.
11. Chiara DC, Xie Y, Cohen JB (1999) Structure of the agonist-binding sites of the Torpedo nicotinic acetylcholine receptor: affinity-labeling and mutational analyses identify γ tyr-111/δarg-113 as antagonist affinity determinants. Biochemistry 38:6689-6698.
12. Cohen BN, Figl A, Quick MW, Labarca C, Davidson N, Lester HA (1995) Regions of β2 and β4 responsible for differences between the steady state dose-response relationships of the α3β2 and α3β4 neuronal nicotinic receptors. J Gen Physiol 105:745-764.
13. Colquhoun D (1998) Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947.
14. Curtis L, Buisson B, Bertrand S, Bertrand D (2002) Potentiation of human α4β2 neuronal nicotinic acetylcholine receptor by estradiol. Mol Pharmacol 61:127-135.
15. Hansen SB, Taylor P (2007) Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on nonalpha-subunit interfaces of heteromeric neuronal nicotinic receptors. J Mol Biol 369:895-901.
16. Harvey SC, Luetje CW (1996) Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J Neurosci 16:3798-3806.
17. Hogg RC, Bertrand D (2007) Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 73:459-468.
18. Hsiao B, Mihalak KB, Repicky SE, Everhart D, Mederos AH, Malhotra A, Luetje CW (2006) Determinants of zinc potentiation on the α4 subunit of neuronal nicotinic receptor. Mol Pharmacol 69:27-36.
19. Hsiao B, Mihalak KB, Magleby KL, Luetje CW (2008) Zinc potentiates neuronal nicotinic receptors by increasing burst duration. J Neurophysiol 99:999-1007.
20. Hurst RS, Hajó s M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffman WE, Piotrowski DW, Groppi VE, Allaman G, Ogier R, Bertrand S, Bertrand D, Arneric SP (2005) A novel allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25:4396-4405.
21. Jensen AA, Frølund B, Liljefors T, Krogsgaard-Larsen P (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 48:4705-4745.
22. Karlin A (2002) Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 3:102-114.
23. Karlin A, Akabas MH (1998) Substituted-cysteine accessibility method. Methods Enzymol 293:123-145.
24. Lee WY, Sine SM (2004) Invariant aspartic acid in muscle nicotinic receptor contributes selectively to the kinetics of agonist binding. J Gen Physiol 124:555-567.
25. Lee WY, Sine SM (2005) Principal pathway coupling agonist binding to channel gating in nicotinic receptors. Nature 438:243-247.
26. Levandoski MM, Piket B, Chang J (2003) The anthelmintic levamisole is an allosteric modulator of human neuronal nicotinic acetylcholine receptors. Eur J Pharmacol 471:9-20.
27. Lyford LK, Sproul AD, Eddins D, McLaughlin JT, Rosenberg RL (2003) Agonist-induced conformational changes in the extracellular domain of α7 nicotinic acetylcholine receptors. Mol Pharmacol 64:650-658.
28. Maelicke A, Albuquerque EX (2000) Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393:165-170.
29. Martin RJ (1997) Modes of action of anthelmintic drugs. Vet J 154:11-34.
30. 2+ potentiation. J Neurosci 28:6884-6894.
31. Nirthanan S, Garcia G 3rd, Chiara DC, Husain SS, Cohen JB (2008) Identification of binding sites in the nicotinic acetylcholine receptor for TDBzl-etomidate, a photoreactive positive allosteric effector. J Biol Chem 283:22051-22062.
32. Palma E, Bertrand S, Binzoni T, Bertrand D (1996) Neuronal nicotinic α7 receptor expressed in Xenopus oocytes presents five binding sites for methyllycaconitine. J Physiol 491:151-161.
33. Paterson D, Nordberg A (2000) Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61:75-111.
34. Romanelli MN, Gualtieri F (2003) Cholinergic nicotinic receptors: competitive ligands, allosteric modulators, and their potential applications. Med Res Rev 23:393- 426.
35. Sallette J, Bohler S, Benoit P, Soudant M, Pons S, Le Novere N, Changeux JP, Corringer JP (2004) An extracellular protein microdomain controls upregulation of neuronal nicotinic acetylcholine receptors by nicotine. J Biol Chem 279:18767-18775.
36. Sanders T, Hawrot E (2004) A novel pharmatope tag inserted into the β4 subunit confers allosteric modulation to neuronal nicotinic receptors. J Biol Chem 279:51460-51465.
37. Sine SM (2002) The nicotinic receptor ligand binding domain. J Neurobiol 53:431-446.
38. Sine SM, Wang HL, Bren N (2002) Lysine scanning mutagenesis delineates structural model of the nicotinic receptor ligand binding domain. J Biol Chem 277:29210-29223.
39. Siu EC, Tyndale RF (2007) Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 47:541-564.
40. Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, Ahring PK, Peters D, Holst D, Christensen JK, Malysz J, Briggs CA, Gopalakrishnan M, Olsen GM (2007) An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323:294-307.
41. Unwin N (2005) Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution. J Mol Biol 346:967-989.
42. Wagner DA, Czajkowski C (2001) Structure and dynamics of the GABA binding pocket: a narrowing cleft that constricts during activation. J Neurosci 21:67-74.
43. Wu TY, Smith CM, Sine SM, Levandoski MM (2008) Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine α3β2 receptors. Mol Pharmacol 74:466-475.
44. Zhong W, Gallivan JP, Zhang Y, Li L, Lester HA, Dougherty DA (1998) From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor. Proc Natl Acad Sci U S A 95:12088-12093.